Fine-tuned test predicts risk of ovarian cancer with great precision
Researchers from KU Leuven, Belgium, have improved a test for ultrasound diagnosis of ovarian tumours. Professors Dirk Timmerman and Ben Van Calster collaborated with scientists from Imperial College London and Lund University.
Ovarian tumours or cysts have either benign or malignant characteristics. Many women with a benign ovarian tumour only need minimally invasive surgery or even no surgery at all. Patients with a malignant tumour, by contrast, have to undergo more radical surgery to remove the tumour. This type of surgery takes much longer and comes with a greater risk of complications. To increase patients' chances of survival, women with a malignant tumour should be treated by a gynaecological oncologist as soon as possible. Therefore, ahead of the surgical intervention, a quick and correct classification of the tumour is very important.
In practice, ovarian tumours are classified as benign or malignant on ultrasound, by means of the popular 'Simple Rules' test. "Until recently, this test was inconclusive for 20-25% of the patients", lead author Professor Timmerman explains. "Our team was able to fine-tune this test. From now on, every patient can get an accurate diagnosis. The new test even provides the exact risk of the tumour being benign or malignant."
Professor Timmerman and the International Ovarian Tumour Analysis team analysed the data of 5,000 patients from 22 different countries. The data were mainly obtained from ultrasound examination of the tumour. This technique allows doctors to, among other features, see how much solid tissue is present in the tumour and how much blood is flowing in it. Based on these data, Professor Timmerman was able to identify the combinations of characteristics that reveal whether a tumour is benign or malignant.
The fine-tuned test is ready for clinical use.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
